Global Cystic Fibrosis Therapeutics Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global cystic fibrosis therapeutics market in its upcoming report titled, “Global Cystic Fibrosis Therapeutics Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global cystic fibrosis therapeutics market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cystic fibrosis therapeutics market report has been segmented on the basis of drug class, route of administration, and region

Request Covid - 19 Impact

Cystic fibrosis is an inherited disorder, a mutation in a gene changes a protein that regulates the movement of salts in and out of cells. It causes several damages to digestive systems, lungs and other organs in the body. However, the features of the disorder and severity varies among the affected individuals. According to British Lung Foundations, in UK, cystic fibrosis accounted for 9,500 hospital admission from year 2008-2012. According to the Cystic Fibrosis Foundation Patient Registry, in the US approximately 1,000 new cases of cystic fibrosis are diagnosed every year.

Increasing number of cases for cystic fibrosis globally is expected to create demand for effective therapeutic treatment option which in turn is expected to drive the growth of global cystic fibrosis market over the forecast period. In addition, market players are developing innovative therapies for the treatment of cystic fibrosis and increasing number of clinical trials and subsequent launch of the products is expected to drive the growth of global cystic fibrosis market over the forecast period.

Huge investment for research and development whereas high cost of the treatment are major factors restraining the growth of the global cystic fibrosis therapeutics market.

North America market dominates the global cystic fibrosis therapeutics market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to well-developed healthcare infrastructure, availability of skilled medical personnel, increasing incidence and awareness about cystic fibrosis in the region. Europe accounts for second-largest revenue share contribution to the global cystic fibrosis therapeutics, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years owing to the increase in R&D funding by public and private organization and increasing prevalence of the disease.

Global cystic fibrosis therapeutics market segmentation;

By drug class:

• Pancreatic enzyme supplements
• Mucolytics
• Bronchodilators
• CFTR modulators

By route of administration:

• Oral drugs
• Inhaled drugs

By region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• AbbVie Inc.
• Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Alcresta Therapeutics Inc.
• Allergan
• AstraZeneca Plc.
• Alaxia